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We report the isolation and characterlzatlon of the human gene encodmg islet amqlold polypeptide (IAPP) Previously characterized cDNA se- 
quence? correspond to three exons of which the first IS noncodmg. A functIonal promoter region was ldentlfied m the 5’ flankmg DNA. however, 
this wah farther upstream than expected Northern blot analyst\ of human msulmoma RNA revealed three IAPP mRNAs of sizes I 2, I 8 and 
7 I kb. m agreement with three polyadenylatlon signals present in the 3’ end of the gene In situ hybrldlzatlon to metaphase chromosomes resulted 
m two dlstmct peaks on chromosome 12, at l?pl2-p13 and l?ql3-ql4. Southern blot analysis of genomlc DNA suggested a single IAPP locus 
but also mdlcated the presence of addItiona homologous sequences m human penomlc DNA 
1. INTRODUCTION 
Islet amyloid polypeptide (IAPP) (also referred to as 
‘amylin’ or ‘diabetes-associated peptide’ (DAP) is the 
major constituent of islet amyloid developing in con- 
junction with type 2 diabetes mellitus in humans and 
cats [l-4] (for a recent review, see [5]). IAPP is 37 
amino acid residues long and displays a 43-46% se- 
quence identity with members of the calcitonin- 
gene-related peptide family (CGRP-1 and -2) [l-7]. 
cDNA cloning of human IAPP has indicated that the 37 
amino acid peptide is a carboxy-terminally amidated 
proteolytic fragment of an 89 amino acid precursor 
[8-lo]. IAPP mRNA expression and immunoreactivity 
is restricted to normal ,B-cells in the islets of Langerhans 
and to insulinomas [3,10-121. The presence of a 
putative signal peptide in the IAPP precursor, the co- 
localization of IAPP and insulin in islet P-cell secretory 
granules [ 13,141 and recent measurements of IAPP 
released from cultured islets [15] suggest that IAPP is 
secreted together with insulin in response to increased 
glucose levels. The normal physiological function of 
IAPP is not known. However, its effects as an inhibitor 
of insulin-stimulated glycogen synthesis in skeletal mus- 
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cle cells in vitro [16] and as an inducer of glucose in- 
tolerance in cats in vivo [ 171 indicate that it might take 
part in the regulation of blood glucose levels. 
The occurrence of islet amyloid in type 2 diabetic sub- 
jects suggests the development of locally increased 
IAPP concentrations in the islets of these individuals. 
Whether this reflects changes in transcription, protein 
synthesis, rate of secretion of paracellular clearance of 
IAPP is not known. In order to study the mechanisms 
for cell-specific expression of the IAPP gene and its 
transcriptional regulation in relation to that of the in- 
sulin gene, we have isolated and structually charac- 
terized the human IAPP gene. We have also identified 
a putative promoter region by means of function and 
present data concerning the sublocalization of the 
hIAPP locus on human chromosome 12. 
2. MATERIALS AND METHODS 
2.1. General methods 
Standard methods m molecular biology [ 181 were utihzed where not 
otherwise indicated. DNA sequencmg was performed usmg dideox- 
ynucleotide methodology [19] following subcloning m h113mpl8/19 
vectors. RNA was prepared using the LiCl/urea method 1201 
2.2. Isolation and characten;atron of human IAPP genomlc 
clones 
Human genormc libraries, made in hEMBL-3 and AEhlBL-4 vec- 
tors using partially Sau3A-digested and fully EcoRl-dlgested human 
macrophage DNA, respectively, were screened at high stringency us- 
ing a human IAPP cDNA sequence corresponding to a 300 bp BarnHI 
fragment of a cDNA clone previously described [9]. hDNA was 
isolated from positive clones and inserts were characterized by diges- 
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tion with vartous restriction enzymes, Southern blotting and DNA se- 
quencing. 
2.3. Promoter constructs, cell transfectrons and CAT assays 
Various length hIAPP 5’ flanking DNA segments were isolated 
and cloned in front of the bacterial chloramphenicol acetyltransferase 
(CAT) gene. The constructs were made by substttuting the rat insulin 
1 promoter/enhancer region in the pOKI vector (provided by Dr 
Thomas Edlund, Umea University; the pOKI vector [21] contains 410 
bp of rat insulin I gene 5 ’ flanking DNA, the enttre CAT coding se- 
quence [22] and simian virus 40 splice and polyadenylation signals in 
the pUC-IS plasmid) with hIAPP sequences. The msulin 5’ sequence 
was excised by HmdIII. HmdIII fragments of 435 and 1388 bp, 
respectively, corresponding to hIAPP genomic sequences extending 
5 ’ from a Hind111 site identified in the 5 ’ untranslated region of the 
previously characterized hIAPP cDNA sequence, were obtained by 
partial HIndI digestion of a plasmid containing a 3 kbp 
BamHI/EcoRI fragment fromXhIAPP-EMBL4b (Fig. 1) in pUC-13. 
The resulting CAT constructs were CsClz gradient purified and 
transfected into the hamster insulinoma cell line HIT-T15 M.2.2.2 
[23,24] (obtained from Dr Thomas Edlund, Umea University), using 
the CaCl2 method. Cell transfection solutions were purchased from 
Pharmacia (Uppsala, Sweden) and used according to manufacturers’ 
recommendations. Forty-etght hours following transfection, cultures 
were harvested, cell lysates prepared and CAT-assays [22] performed 
using [‘4C]chloramphenicol (Amersham, UK). 
2.4. Prtmer-extension and RNase-protectton assavs 
Primer extension [IS] was performed using the oligonucleotide 
5 ’ AAGCTTCAAGAAAAGAGTCCAA (complementary to posi- 
tions - 88 to - 67 in Fig. 1). Briefly, the primer was annealed over- 
night to 1 pg of heat-denatured poly(A+) RNA in a solution contain- 
ing RNase inhibitor and actinomycin D. Extension was performed m 
the presence of [ru-3ZP]dCTP for 30 min at 37°C using AMV reverse 
transcriptase (Pharmacia). For RNase A protection assays [IS], 
various DNA fragments covering the putattve promoter region were 
subcloned in Bluescript vectors and “P-labeled cRNA synthesized 
following linearization of the vector with an appropriate restrtction 
enzyme. The cRNA probe was gel-purified and hybridized to 1 ,ug of 
poly(A+) RNA at 45°C for at least 12 h. RNase A digestion was at 
30°C for 30 min using an enzyme concentration of 75 /g/ml. Both 
primer extension and Rnase A protection reactions were analyzed on 
8% polyacrylamide/urea sequencing gels and product sizes were 
estimated by comparison with Ml3 sequences run in parallel. 
2.5. In sttu hybrtdization 
A 300 bp fragment derived from the 5’ region of a hlAPP cDNA 
clone [IO] was labeled by nick-translation with 13H]dTTP and 
[3H]dATP to high specific acttvtty (4x 10’ cpm/pg DNA). Pro- 
metaphase chromosomes, prepard from methotrexate-synchronized 
normal peripheral lymphocytes from two donors, were hybridized in 
situ as described previously [25,26]. The hybridizations were perform- 
ed in a moist chamber at 37°C for 16 h at a probe concentration of 
20 or 100 ng/ml in the hybridization mixture. Washes after hybridiza- 
tion were at 40 or 43°C. Autoradiographs were exposed for 6-16 days 
and subsequently developed and G-banded [27]. Metaphases were 
analyzed directly under the microscope for the presence of silver 
grains overlaying or touching the chromatides. 
3. RESULTS 
3.1. Characterization of human IAPP genomic clones 
The outline of two overlapping hIAPP genomic 
clones, a consensus restriction map of the hIAPP locus 
and the DNA sequences of exons, exon/intron junc- 
tions and a 5’ flanking region are shown in Fig. 1. 
Previously known mRNA (cDNA) sequence localized 
to three regions (exons) being 112, 95 and 390-1244 bp 
long, respectively (the variation of the length of the 3rd 
region reflects the use of alternative polyadenylation 
signals [S-lo]). The intron between the first of these was 
only 326 bp whereas the second intron was approxi- 
mately 5 kb. Comparison with the cDNA sequence 
[8-IO] shows that the first exon is non-coding, the se- 
cond exon contains the translation initiation site and 
encodes the sign1 sequence and part of the N-terminal 
propeptide of the hIAPP precursor and the third exon 
encodes the remaining part of the N-terminal propep- 
tide, mature IAPP as well as the C-terminal propep- 
tide(s). Three consecutive polyadenylation signals are 
found in the 3rd exon, all of which appear to be utiliz- 
ed, as judged from the characterization of polyadeny- 
lated cDNAs [g-lo]. An Alu repeat sequence is situated 
between the 1st and 2nd of these, and has been shown 
to be included in cDNAs polyadenylated at the 2nd or 
3rd of the polyadenylation signals [8-lo]. 
3.2. Primer-extension, Northern blot and RNase 
protection analyses: 
The largest hIAPP cDNA clones characterized to 
date have their 5 ’ end close to two Hind111 sites located 
in the noncoding exon (Fig. 1) [g-lo]. To map the 
transcriptional start site, primer-extension analysis was 
performed using a synthetic antisense oligonucleotide 
primer complementary to positions -88 to -67 in 
Fig. 1. Extended products, up to 40 nucleotides long, 
were seen using IAPP-positive human insulinoma 
mRNA as template, but not with IAPP-negative 
mRNA (Fig. 2a). The ‘ladder’ of products indicates 
some degradation in the 5 ’ end of the IAPP mRNA or 
incomplete extention, possibly due to mRNA secondary 
structures. The latter seemed most probable in the light 
of the hIAPP mRNA sizes revealed by Northern blot- 
ting (Fig. 2b). The size differences of the three 
transcripts (1.2, 1.8 and 2.1 kb), identified specifically 
in human insulinoma RNA, correlate with the positions 
of the three polyadenylation signals (Fig. 1). However, 
the coding sequences between the polyadenylation 
signals and the 5 ’ ends of previously characterized 
cDNA clones [g-10] and our primer-extension products 
(Fig. 2a) is only about 0.6, 1.2 and 1.5 kb, respectively. 
A comparison with the sizes of the mRNAs indicates the 
existence of some 600 bp of 5’ untranslated sequence 
not present in the cDNA clones. 
To explore the possibility of additional 5’ untrans- 
lated sequence, RNase A protection assays were per- 
formed using human insulinoma poly(A+) RNA and 
32P-labeled antisense RNA corresponding to different 
regions of the 5’ flanking sequence. Fig. 3 illustrates 
the probes used and shows the fragment protected. The 
435 bp Hind111 fragment extending from the 5’ end of 
the cDNAs protected a slightly smaller RNA fragment 
(Fig. 3), whereas the 125 bp KpnI/HindIII fragment 
immediately upstream of the 435 bp region, did not give 
any detectable protection (data not shown). Fragments 
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Fig. 1. (a) Outline of the hIAPP cDNA as previously characterized [S-10] and its relationshtp to the gene as determined through the characteriza- 
tion of two A-clones. Withm the protein-coding sequence in the cDNA (boxed), the stgnal sequence (SS) and IAPP-encoding region are indicated. 
In the gene, the posttions of sequence corresponding to the cDNA (exons) are indicated (filled boxes). Restriction sites for EcoRI (E), BumHI (B) 
and HrndIII (H) are marked. (b) Sequence of the hIAPP gene and 5 ’ flankmg DNA. Small letters are used for known intron sequences. Restriction 
sites used for promoter-CAT constructs are indicated as well as two Alu repeat sequences, one in the 5’ flanking DNA and one in the 3’ 
untranslated region. The sequence complementary to the oligonucleotrde used for prtmer extension analysis is overlined and the positton of primer 
extension products marked by arrows Folyadeny~ation signals in the 3’ part of the gene are underlined. 
I”E fii corresponding to regions further upstream protected a 
I I I I 
series of small fragments, ranging from 20 to 70 bp 
.” 
nt 
(data not shown), in agreement with the presence of an “+G %a Alu repeat sequence in this region (Fig. 1). Our data are 
thus compatible with the existence of a large portion of 
5 ’ untranslated sequence which is missing in the hIAPP 
cDNA clones isolated so far [S-lo]. The reason for this, 
as well as for the presumably incomplete primer- 
extension shown in Fig. 2a, is not known. However, 
poor reverse transcription of long 5’ untranslated se- 
quences is not uncommon and may be due to the 
presence of stable secondary structures in these regions. 
I 40 abcdefghijkl 
kb 
3.3. F~nct~or~ai identification of a promoter region 
Two DNA fragments, extending 435 and 1388 bp, 
respectively, from the most 5 ’ of the two Hind111 sites 
Ftg. 2. (a) Primer extension analysis using human insulinoma (Ins) or melanoma (mel) mRNA (from the human melanoma cell line WM 266-4 
[37]) in comparison with an Ml3mpl8 sequence. Two independent reactions are shown. nt, nucleotides. (b) Northern blot analysts of poly(A+) 
RNA f 10 gg/lane) from human fibroblasts (lane a), human WM 266-4 melanoma cells [37] (lane b), a primary human insulinoma (lane c). human 
U-343 MGa Cl 2:6 giiobfastoma cells 1381 (lane d), human A431 epidermal carcinoma cells 1391 (lane ef, rat liver (lane fl, rat spleen (lane g), 
rat brain (lane h), rat kidney (lane I), rat intestine (lane j), rat testis (lane h) and porcme thyroid (lane I). The probe was a “P-labeled hIAPP 
cDNA probe. kb = kilobases. 
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Fig. 3. RNase protectton analysis of human msuhnoma RNA. (a) 
Illustration of the 5’ flankmg regton of the gene and the probes used. 
(b) Autoradiogram showmg a 420 hp protected fragment in human 
insulirlorrla RNA usmg probe A (lane 2). Thrs product was absent in 
the control reactron utihzing tRNA instead of msulinoma poly(A+) 
RNA (lane 4). The protected fragment was slightly smaller than the 
probe used (lane 1). Fragment sizes v%ere estimated by comparison 
with the M13mp18 sequence run m parallel (lane 3). H -I-irndfIt site, 
K=A’pnI sate; bp, base pairs. 
a. b. 
Fig. 5. Dtstrtbutton of labeled sites on human chromosome 17 (a) 
after in situ hybridrzation to a ‘H-labeled hlAPP cDNA probe (20 ng 
probe:ml ~l~bridi7atlon soiutron), and G-banded hybridized chromo- 
somes 12 (b) with grams at 12~13 and 17ql3. respectively. 
found in the untranslated sequence of the ONA clones, 
were cloned in correct and reversed orientation in front 
of the bacteria1 cloramphenicol acetyltransferase (CAT) 
gene and transfected into hamster insulinoma (HIT-T1 5 
M.2.2.2) cells. Significant CAT activity was seen only 
when the vector containing the correctly oriented 1388 
bp fragment was used (Fig. 4). Neither the 1388 bp 
fragment in reversed orientation nor the 435 bp frag- 
ment in correct or reversed orientation resulted in 
significant CAT activity. 
At present, we do not know the location of the 
hIAPP promoter within the 1388 bp fragment. A con- 
struct carrying its 5 ’ 933 bp in correct orientation also 
induced CAT activity in HIT cells (data not shown), in- 







Fig. 4. CAT assays using HIT-T15 M.2.1.2 c&s. Constructs con- 
taming various length and orientatmn DNA fragments from the 5’ 
flanking regton of the hIAPP gene (Indicated at the top of the figure; 
compare with Fig. la) tn front of a CAT gene, were assayed for 
promoter activity in conlparison with a rat insulin I promoter (rms)- 
CAT construct. Arrows indicate orientatton of the 5’ flankmg DNA 
fragment. H = Ii’rndIII site. 
Fig 6. Southern blot analysts of human chromosomal DNA samples 
digested ntth EcoRi (E), Ba/nHI (B), NrndIII (H), Xhal (S) and WI 
(P), respecttvely. The blot was hybridized nith a “P-labeled 300 bp 
,YcoRI’BurnHI fragment corre~portdmg to the 5’ end of a precrously 
descrtbed hIAPP cDN.4 clone (IO]. Numbers refer to approximate 
stzes (in kilobase pairs) of each fragment. Arroas indicate additional, 
vveakty hybridizing bands 
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dicating an upstream location in agreement with the 
estimated mRNA sizes. 
The 1388 bp human IAPP 5’ flanking sequence was 
much less active in HIT cells than a construct contain- 
ing 410 bp of rat insulin gene 5’ flanking sequence 
(Fig. 4). This might reflect the respective activities of 
the two endogenous promoters in HIT cells and agrees 
with the finding that the level of IAPP mRNA is ap- 
proximately lOO-fold less than that of insulin mRNA in 
these cells (Betsholtz et al., unpublished result). 
However, we cannot exclude the possibility that se- 
quences of importance for efficient IAPP expression in 
HIT cells (i.e. tissue-specific enhancers) are located 
upstream of the 1388 bp region analyzed in this study. 
3.4. Chromosomal sublocalization of the hIAPP gene 
The hIAPP gene has previously been regionally map- 
ped to the 12pter-q14 by using a panel of somatic cell 
hybrids [28]. For sublocalization of hIAPP, 64 cells 
with silver grains located on chromosome 12 were 
analyzed. Two different sites of hybridization were 
detected, one on the long arm and one on the short arm. 
Out of the 67 grains recorded, 27 (40%) clustered at 
12q13-q14, and 20 (30%) at 12p12-p13 (Fig. 5). The re- 
maining grains were randomly distributed over 
chromosome 12. The same hybridization pattern was 
obtained both at standard and high stringency hybri- 
dization conditions (data not shown). The only dif- 
ference that could be noted was that hybridization at a 
probe concentration of 100 ng/ml resulted in a 
somewhat greater accumulation of grains at 12ql3-q14 
as compared to 12p12-~13. This raises the question 
whether more than one IAPP gene is present on human 
chromosome 12. Southern blot analysis (Fig. 6) is con- 
sistent with a single IAPP locus in the human genome, 
but the existence of several faintly hybridizing restric- 
tion fragments, of sizes not predictable from the struc- 
ture of the cloned IAPP locus, suggests that additional 
IAPP-related sequences might be found in the human 
genome. 
4. DISCUSSION 
We report here the structural characterization and 
chromosomal sublocalization of the human IAPP gene. 
Given the fact that it encodes a precursor protein of on- 
ly 89 amino acids and a mature protein product which 
is only 37 residues long, the gene is surprisingly com- 
plex. Thus, it consists of at least three exons, of which 
the first is non-coding. Exon 2 contains the translation 
initiation codon and encodes the signal peptide as well 
as part of the N-terminal propeptide. The mature IAPP 
coding sequence falls entirely within exon 3, as do the 
C-terminal propeptide(s) and 3 ’ untranslated sequence. 
The identification of a functional IAPP promoter 
region is a first step in unravelling the mechanisms in- 
volved in the regulation of this gene. The coexpression 
of IAPP and insulin in pancreatic p-cells [3,10-121, the 
presumed cosecretion of the two hormones in response 
to increased blood glucose levels [13-151 and their 
reported opposite effects on the glucose metabolism in 
skeletal muscle cells [16] and on blood glucose levels 
[17] highlight questions concerning how their transcrip- 
tional regulation. In the insulin gene, transcription is 
regulated by elements in the 5 ’ flanking DNA that bind 
,%cell-specific nuclear proteins [21,24,29,30]. However, 
no extensive homologies could be seen between the 
hlAPP and insulin 5’ flanking regions. This may in- 
dicate that the two genes have different transcriptional 
regulation. Such a notion is supported by non- 
correlating insulin and IAPP mRNA and protein ex- 
pression patterns in cultured insulinoma cell lines (0. 
Madsen, personal communication), human insulinoma 
primary tumors (Westermark et al., unpublished obser- 
vations) and in experimentally diabetic rats [31]. 
During the preparation of this manuscript, Nishi et 
al. reported on the structure and chromosomal localiza- 
tion of the human IAPP gene [32]. In contrast to us, 
they report a single site for IAPP-hybridizing sequences 
on chromosome 12. This site coincides with one of our 
localizations, that on 12p12-~13, which is therefore 
likely to constitute the site of the hlAPP gene. Recent 
in situ data from a third group also support the assign- 
ment to 12p [33]. Interestingly, our second hybridiza- 
tion site at 12q13-q14 coincides with a suggested alter- 
native localization for the hIAPP gene [33]. We do not 
know the reason for the two subregional localizations 
described for hIAPP, but different hybridization condi- 
tions used by the various groups could have given 
hybridization to an IAPP-related sequence in addition 
to the authentic hIAPP locus, also being present on 
chromosome 12. 
Nishi et al. also reported a transcription initiation 
site, mapped by primer extension and RNase protection 
analysis, which corresponds to position - 117 in Fig. 1 
and thus indicates a promoter region distinct from ours. 
The basis for this discrepancy is also unknown. A possi- 
ble explanation might be that alternative promoters ex- 
ist for the hIAPP gene and that the utilization of these 
promoters is variable in insulinomas. 
Further insight into the regulation of the IAPP gene 
might have relevance for the understanding of type 2 
diabetes mellitus. Evidence is accumulating that this 
disease is associated with an increased expression of 
IAPP. Islet amyloid is deposited in diabetic individuals 
of species with an amyloidogenic structure of IAPP 
[l-4,10,34,35]. Moreover, increased IAPP immuno- 
reactivity has been shown in conjunction with 
prediabetic states in the cat [36]. It wiI1 be important to 
know whether this reflects changes in the transcription 
of the IAPP gene and if so, whether disturbances in this 
regulation may be caused by hereditary or dietary fac- 
tors. 
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